Physician

Daron Gene Street, M.D.

According to 2025 Medicare claims, Daron Street, M.D. (NPI: 1083656912) practices gynecologist/oncologist in the Tulsa, OK market, with the plurality of this provider's patient population coming from Tulsa, OK. This provider's primary affiliated billing organization is OKLAHOMA CANCER SPECIALISTS AND RESEARCH INSTITUTE LLC (NPI: 1962876045; TIN: 383983999) and primary practice location at 74146-6236.

Street's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 388 traditional Medicare patients, billed 93,810 HCPCS/CPT codes, and received $1,888,395 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 605 prescription claims across 136 beneficiaries totaling $299,713 in drug costs, led by Zejula (Niraparib Tosylate). 2015 DME data shows 21 claims. Open Payments data shows 111 records totaling $134,498. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $994,413 and ending at $1,888,395. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $39,975 and ending at $299,713. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	533	91,046	$994,413
2016	803	156,318	$1,766,673
2017	690	131,941	$1,785,164
2018	689	116,639	$1,797,834
2019	601	61,458	$926,680
2020	612	68,191	$1,232,457
2021	740	126,974	$1,942,615
2022	535	103,505	$1,647,208
2023	378	92,684	$1,431,168
2024	388	93,810	$1,888,395

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	185	968	$39,975
2016	242	1,159	$63,839
2017	191	936	$225,549
2018	201	1,118	$278,581
2019	173	917	$564,261
2020	144	798	$435,069
2021	154	785	$295,784
2022	180	763	$151,538
2023	127	573	$324,133
2024	136	605	$299,713

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	21	$1,082
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	128	249	$90
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	45	81	$88
96367	Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less	86	311	$20
96372	Injection of drug or substance under skin or into muscle	79	122	$10
J1100	Injection, dexamethasone sodium phosphate, 1 mg	77	1,627	$0

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Zejula	Niraparib Tosylate	11	330	$203,922
Eliquis	Apixaban	12	360	$7,149
Estradiol	Estradiol	36	2,243	$1,572
Megestrol Acetate	Megestrol Acetate	25	1,020	$1,518
Gabapentin	Gabapentin	43	1,639	$665

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	42	$3,920	GlaxoSmithKline, LLC.
Research Payments	Reported research-related payment or transfer-of-value amount.	69	$130,578	TRILLIUM THERAPEUTICS USA, LLC
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Daron Gene Street, M.D.?

Tedicare shows public-source Medicare data for Daron Gene Street, M.D. (NPI 1083656912), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Daron Gene Street, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Daron Gene Street, M.D.?

Daron Gene Street, M.D. is linked to OKLAHOMA CANCER SPECIALISTS AND RESEARCH INSTITUTE LLC (billing NPI 1962876045) in the available physician profile data.

Does Daron Gene Street, M.D. have Open Payments data?

Daron Gene Street, M.D. has 111 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.